Quantcast

Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.

Research paper by Miriam M Samuel, Daniel D Bradshaw, Melissa M Perry, Sum Yee SY Chan, Rageshri R Dhairyawan, Laura L Byrne, Katherine K Smith, Judith J Zhou, Charlotte Eve CE Short, Claire C Naftalin, Ngozi N Offodile, Sundhiya S Mandalia, Sherie S Roedling, Rimi R Shah, Gary G Brook, et al.

Indexed on: 21 Oct '14Published on: 21 Oct '14Published in: Infectious Diseases in Obstetrics and Gynecology



Abstract

There are few data regarding the tolerability, safety, or efficacy of antenatal atazanavir. We report our clinical experience of atazanavir use in pregnancy.A retrospective medical records review of atazanavir-exposed pregnancies in 12 London centres between 2004 and 2010.There were 145 pregnancies in 135 women: 89 conceived whilst taking atazanavir-based combination antiretroviral therapy (cART), "preconception" atazanavir exposure; 27 started atazanavir-based cART as "first-line" during the pregnancy; and 29 "switched" to an atazanavir-based regimen from another cART regimen during pregnancy. Gastrointestinal intolerance requiring atazanavir cessation occurred in five pregnancies. Self-limiting, new-onset transaminitis was most common in first-line use, occurring in 11.0%. Atazanavir was commenced in five switch pregnancies in the presence of transaminitis, two of which discontinued atazanavir with persistent transaminitis. HIV-VL < 50 copies/mL was achieved in 89.3% preconception, 56.5% first-line, and 72.0% switch exposures. Singleton preterm delivery (<37 weeks) occurred in 11.7% preconception, 9.1% first-line, and 7.7% switch exposures. Four infants required phototherapy. There was one mother-to-child transmission in a poorly adherent woman.These data suggest that atazanavir is well tolerated and can be safely prescribed as a component of combination antiretroviral therapy in pregnancy.